Table 5.
Baseline characteristics of eligible non-responders (alive and recurrence-free patients) who were invited to, but did not, participate in HRQoL analyses
| Three-arm randomization |
Short-course radiotherapy comparison |
||||
|---|---|---|---|---|---|
| SRT (n = 19) | SRT-delay (n = 21) | LRT-delay (n = 13) | SRT (n = 59) | SRT-delay (n = 62) | |
| Age (years) | 68 (56–77) | 69 (60–78) | 63 (48–85) | 67 (49–81) | 66 (42–86) |
| Sex | |||||
| Men | 12 (63.2%) | 7 (33.3%) | 5 (38.5%) | 34 (57.6%) | 32 (51.6%) |
| Women | 7 (36.8%) | 14 (66.7%) | 8 (61.5%) | 25 (42.4%) | 30 (48.4%) |
| Height from anal verge (cm) | |||||
| 0–5 | 6 (31.6%) | 10 (47.6%) | 5 (38.5%) | 22 (37.3%) | 19 (30.6%) |
| 6–10 | 8 (42.1%) | 9 (42.9%) | 8 (61.5%) | 21 (35.6%) | 31 (50.0%) |
| 11–15 | 5 (26.3%) | 2 (9.5%) | 0 (0%) | 16 (27.1%) | 12 (19.4%) |
| Type of surgery | |||||
| AR | 12 (63.2%) | 10 (47.6%) | 9 (69.2%) | 38 (64.4%) | 36 (58.1%) |
| APE | 6 (31.6%) | 10 (47.6%) | 4 (30.8%) | 20 (34%) | 24 (38.7%) |
| Hartmann’s | 1 (5.3%) | 1 (4.8%) | 0 (0%) | 1 (21.7%) | 2 (3.2%) |
| LE | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| NR | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| YpStage | |||||
| I* | 3 (15.8%) | 11 (52.4%) | 7 (53.9%) | 12 (20.3%) | 27 (43.5%) |
| II | 7 (36.8%) | 6 (28.6%) | 5 (38.5%) | 24 (40.7%) | 17 (27.4%) |
| III | 9 (47.4%) | 3 (14.3%) | 1 (7.7%) | 23 (39.0%) | 17 (27.4%) |
| IV | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| X | 0 (0%) | 1 (4.8%) | 0 (0%) | 0 (0%) | 1 (1.6%) |
Data are median (range) or n (%). *Includes patients with complete response. HRQoL, health-related quality of life; SRT, short-course radiotherapy of 5 × 5 Gy, with surgery within 1 week; SRT-delay, short-course radiotherapy of 5 × 5 Gy, with a delay of 4–8 weeks to surgery; LRT-delay, long-course radiotherapy of 25 × 2 Gy, with surgery after 4–8 weeks; AR, anterior resection; APE, abdominal perineal excision; LE, local excision; NR, no resection.